Zhang Fan, Wu Zhongjun
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Biochimie. 2017 Sep;140:66-72. doi: 10.1016/j.biochi.2017.06.007. Epub 2017 Jun 15.
In this study, we assessed the expression and functions of microRNA-511-3p (miR-511-3p) in human prostate cancer (CaP).
Gene expressions of miR-511-3p in CaP cells and human CaP tumors were assessed by qPCR. In VCaP and PC3 cells, miR-511-3p was overexpressed by lentivirus. The functions of miR-511-3p upregulation in regulating in vitro cancer proliferation, migration and in vivo cancer growth were assessed by MTT, transwell and transplantation assays, respectively. Downstream target gene of miR-511-3p, AKT3, was verified by dual-luciferase activity and qPCR assays. AKT3 was then overexpressed in miR-511-3p-upregulated CaP cells to assess its functions in miR-511-3p-mediated cancer regulation.
MiR-511-3p is significantly downregulated in CaP cell lines, and human CaP tumors. MiR-511-3p was further downregulated in T3/T4-staged CaP tumors and closely correlated with shorter overall survival among CaP patients. In VCaP and PC3 cells, lentiviral-induced miR-511-3p upregulation was acting as a tumor suppressor by inhibiting in vitro cancer proliferation, migration and in vivo transplantation. Human AKT3 gene was confirmed to be the downstream target of miR-511-3p in CaP. In miR-511-3p-upregulated VCaP and PC3 cells, forced-overexpression of AKT3 reversed the tumor suppressive effects of miR-511-3p in CaP.
MiR-511-3p may serve as a prognostic factor and tumor suppressor in CaP, very likely through inverse regulation of its downstream target gene of AKT3.
在本研究中,我们评估了微小RNA-511-3p(miR-511-3p)在人类前列腺癌(CaP)中的表达及功能。
通过定量聚合酶链反应(qPCR)评估miR-511-3p在CaP细胞和人类CaP肿瘤中的基因表达。在VCaP和PC3细胞中,通过慢病毒使miR-511-3p过表达。分别通过MTT法、Transwell法和移植实验评估miR-511-3p上调在体外对癌症增殖、迁移以及在体内对癌症生长的调节功能。通过双荧光素酶活性和qPCR实验验证miR-511-3p的下游靶基因AKT3。然后在miR-511-3p上调的CaP细胞中使AKT3过表达,以评估其在miR-511-3p介导的癌症调节中的功能。
miR-511-3p在CaP细胞系和人类CaP肿瘤中显著下调。在T3/T4期CaP肿瘤中miR-511-3p进一步下调,且与CaP患者较短的总生存期密切相关。在VCaP和PC3细胞中,慢病毒诱导的miR-511-3p上调通过抑制体外癌症增殖、迁移和体内移植发挥肿瘤抑制作用。人类AKT3基因被证实为CaP中miR-511-3p的下游靶基因。在miR-511-3p上调的VCaP和PC3细胞中,强制过表达AKT3可逆转miR-511-3p对CaP的肿瘤抑制作用。
miR-511-·3p可能作为CaP的一个预后因素和肿瘤抑制因子,很可能是通过对其下游靶基因AKT3的反向调节来实现的。